Biomarkers of response to immunotherapy in early stage non-small cell lung cancer-Reference-Cited by-同舟云学术

Biomarkers of response to immunotherapy in early stage non-small cell lung cancer

Published:2023-05 Issue: Volume:184 Page:179-196
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Roulleaux Dugage Matthieu^ORCID,Albarrán-Artahona Víctor,Laguna Juan Carlos,Chaput Nathalie,Vignot Stéphane^ORCID,Besse Benjamin,Mezquita Laura,Auclin Edouard^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference104 articles.

1. A guide to cancer immunotherapy: from T cell basic science to clinical practice;Waldman;Nat Rev Immunol,2020

2. Tumor immunology and tumor evolution: intertwined histories;Galon;Immunity,2020

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

4. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

5. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer;International Immunopharmacology;2024-08

2. Increasing serum complement component 1q is associated with worse prognosis in advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a single-center, retrospective study;Journal of Thoracic Disease;2024-05

3. Value of computed tomography radiomics combined with inflammation indices in predicting the efficacy of immunotherapy in patients with locally advanced and metastatic non-small cell lung cancer;Journal of Thoracic Disease;2024-05

4. Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non–small cell lung cancer;The Journal of Thoracic and Cardiovascular Surgery;2024-05

5. Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy;Frontiers in Immunology;2024-03-21